GHRP-6

GHRP-6 is a synthetic hexapeptide that mimics ghrelin, the hunger hormone, at the pituitary and hypothalamus. Unlike recombinant HGH, it doesn't add exogenous growth hormone — it forces your own pituitary to release a larger, cleaner GH pulse than it would on its own. Everything downstream (IGF-1, recovery, sleep depth, appetite, connective-tissue repair) flows from that single mechanism.

GHS-R1a Activation and Pulsatile GH Release#

GHRP-6 binds the growth hormone secretagogue receptor 1a (GHS-R1a) on pituitary somatotrophs and hypothalamic neurons — the same receptor endogenous ghrelin activates. Binding triggers phospholipase C → IP3 → intracellular Ca²⁺ release inside the somatotroph, which drives a sharp pulse of GH into circulation within 15–30 minutes of injection. Because the mechanism is pulsatile rather than continuous, the GH release mimics your natural rhythm instead of flattening it the way constant recombinant HGH does.

"GHRP-6 produced a dose-related GH response, with a plateau at approximately 1 microgram/kg, and acted synergistically with GHRH to further augment GH secretion." — Bowers CY et al., Journal of Clinical Endocrinology & Metabolism, 1990

The plateau is why 100 µg per pulse is already close to the ceiling in a normal-sized adult — pushing to 300–400 µg mostly buys side effects, not more GH.

GHRH Synergy — Why the Stack Matters#

GHS-R1a and the GHRH receptor are two separate pathways that both converge on GH release, and they amplify each other. A GHRH analog (mod-GRF 1-29, CJC-1295) opens the "gate" on the somatotroph; GHRP-6 simultaneously suppresses somatostatin (the brake on GH release) and stimulates release. Co-administered, the GH pulse is larger than either peptide can produce alone — typically 2–5× the AUC of monotherapy. This is why the community rule is non-negotiable: GHRP-6 is always run with a GHRH analog. Solo GHRP dosing leaves most of the mechanism on the table.

Downstream IGF-1 Elevation#

The GH pulse reaches the liver and drives hepatic IGF-1 synthesis over the following 12–24 hours. IGF-1 is the real workhorse — it mediates most of what users actually notice: improved nitrogen retention, connective-tissue remodelling, slow lean-tissue accrual, and skin/hair quality changes. On a proper 3-pulse-per-day protocol with a GHRH analog, fasted IGF-1 commonly rises 50–100 ng/mL above baseline by week 4–6. That's the bloodwork marker worth tracking; chasing acute GH levels is pointless because the pulse is over in an hour.

Ghrelin Mimicry — Appetite, Cortisol, Prolactin#

Here's where GHRP-6 diverges from "cleaner" secretagogues like ipamorelin. As a full ghrelin mimetic, it activates the same hypothalamic NPY/AgRP circuits that ghrelin does, producing an intense hunger flash within 15–30 minutes. This is the signature effect — useful for bulking and hardgainers, a dealbreaker on a cut. The same cross-reactivity produces a modest ACTH/cortisol bump and a mild prolactin rise that newer, more selective peptides avoid.

"GHRP-6 increased both ACTH and cortisol, as well as prolactin levels, distinguishing it from newer, more selective secretagogues such as ipamorelin." — Raun K et al., European Journal of Endocrinology, 1998

At 100–150 µg per pulse these rises are subclinical for most users. At 200+ µg three times daily for months, they're worth respecting — especially if you're stacking 19-nor compounds that already raise prolactin.

Pro-Angiogenic and Cytoprotective Signalling#

GHS-R1a activation isn't limited to the pituitary. The receptor is expressed on vascular endothelium, and GHRP-6 drives MEK/ERK and PI3K/Akt signalling in endothelial cells, promoting capillary formation and tissue protection at injury sites.

"Ghrelin induced angiogenesis... through specific activation of MEK/ERK and PI3K/Akt signal pathways in endothelial cells, implicating cytoprotective and pro-angiogenic potential of GHRP-6 as a ghrelin mimetic." — Li L et al., Peptides, 2011

Practically, this is the rationale for stacking GHRP-6 with BPC-157 or TB-500 on tendon and ligament protocols — the GH/IGF-1 axis drives collagen synthesis while GHS-R1a-mediated angiogenesis improves perfusion at the repair site. It's a different mechanism from BPC-157's VEGFR2 pathway but complementary, which is why the two peptides are often run together for elbow, shoulder, and patellar tendinopathy.

Common (most users)#

• Intense hunger flash within 15–30 min of injection — the signature of this peptide, driven by hypothalamic NPY/AgRP activation. Mitigation: time the shot 20–30 min before a planned meal if bulking; if it's landing too hard, drop to 75–100mcg per pulse or switch to ipamorelin.
• Injection-site redness, warmth, or itch from mild mast-cell/histamine activation. Mitigation: rotate sites, inject slowly, let the solution come to room temp before pinning.
• Transient head-flush, tingling, or light-headedness in the first 5–10 min post-injection. Mitigation: sit down for the first couple of doses until you know your response; resolves on its own.
• Lethargy or a "sleepy wave" 15–30 min after the pulse, especially on the pre-bed shot. Mitigation: lean into it — schedule the third pulse right before sleep rather than fighting through it.
• Vivid dreams and deeper sleep from the nocturnal GH pulse. Mitigation: none needed — this is a feature, not a bug. If it crosses into insomnia, move the pre-bed shot 30–60 min earlier.
• Mild water retention / puffy face or hands in the first 2–3 weeks. Mitigation: keep sodium sane, stay hydrated; usually settles as the body acclimates to the IGF-1 rise.

Uncommon (dose-dependent or individual)#

• Numb fingers, wrist tingling, carpal-tunnel-like symptoms — the classic GH-pulse complaint, typically at 200mcg+ per pulse or when stacked aggressively with a GHRH analog. Mitigation: drop per-pulse dose back to 100–150mcg; symptoms clear within a week.
• Elevated fasting glucose / mild insulin resistance drift with chronic multi-pulse dosing. Mitigation: check fasting glucose and HbA1c once per 3-month run; if glucose trends up, shorten the cycle or cut to 2 pulses/day.
• Cortisol and ACTH elevation — modest at 100–150mcg but measurable, and higher than with cleaner secretagogues like ipamorelin (Raun et al. 1998; Arvat et al. 1997). Mitigation: cap per-pulse dose at 150mcg, don't run more than 3 pulses/day, and cycle off or rotate to ipamorelin after 12–16 weeks.
• Mild prolactin rise — usually subclinical, but stacks additively with 19-nor AAS (nandrolone, trenbolone). Mitigation: if you're running a nandro or tren cycle and seeing prolactin sides, either switch the secretagogue to ipamorelin or add a low-dose caber. Pull prolactin on bloodwork if symptomatic.
• Gynecomastia-like sensitivity in prolactin-sensitive users on 19-nor cycles. Mitigation: same as above — this is almost always a prolactin-stacking issue, not a direct estrogenic effect.
• GH-axis desensitization with uninterrupted long-term use — pulses get weaker, IGF-1 plateau erodes. Mitigation: cap runs at 16 weeks, cruise 4+ weeks off, or rotate through ipamorelin / MK-677 between GHRP-6 blocks.
• Blunted response from poor timing (not technically a side effect, but the #1 "it doesn't work" complaint). Mitigation: empty stomach is non-negotiable — 2h after food, 20–30 min before the next meal.

Rare but serious#

• Accelerated growth of occult tumors — GH/IGF-1 are mitogenic. Any unexplained rapid weight loss, persistent pain, or new lumps during a cycle warrants stopping and investigating.
• Worsening of proliferative diabetic retinopathy — new floaters, visual changes, or flashes mean stop immediately and get an eye exam.
• Severe hypersensitivity / systemic allergic reaction — rare but reported with peptide products; hives, throat tightness, or wheezing = stop and seek care.
• Symptomatic hyperprolactinemia — persistent galactorrhea, sustained libido crash, or erectile dysfunction that doesn't track with estrogen/AAS management. Pull prolactin, discontinue, consider caber if confirmed.

Hard contraindications#

• Active malignancy or cancer history — do not run GH secretagogues. GH/IGF-1 elevation is mitogenic and can accelerate occult disease.
• Active or untreated proliferative diabetic retinopathy — GH pulses worsen the condition.
• Prolactinoma or clinically elevated baseline prolactin — pick a cleaner GHRP (ipamorelin) instead.
• Pregnancy and lactation — no safety data; do not use.
• Uncontrolled diabetes — get glucose managed before adding a compound that nudges insulin resistance.

Gender, fertility, and PCT#

Women can run GHRP-6 at the same per-pulse doses as men — it is non-androgenic and carries no virilization risk. Most female users who've tried it migrate to ipamorelin specifically to dodge the appetite surge, which is harder to manage on a cut. GHRP-6 does not suppress the HPTA, so there is no PCT requirement — you can stop the peptide cleanly at the end of a cycle with no testosterone recovery protocol needed. Fertility is unaffected in either sex. For users running it on-cycle alongside AAS, the peptide side has no bearing on your PCT — run PCT based on the AAS protocol, not the GHRP.